Reports safety and clinical outcomes in participants with Parkinson’s disease, indicating long-term effects of bemdaneprocel administration.
To report safety and clinical outcomes in participants with Parkinson’s disease (PD) 3 years after receiving bemdaneprocel.
No takes yet. Share an insight, caveat, or question.
Sarva et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: